File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Cross-protection of newly emerging HPAI H5 viruses by neutralizing human monoclonal antibodies: A viable alternative to oseltamivir

TitleCross-protection of newly emerging HPAI H5 viruses by neutralizing human monoclonal antibodies: A viable alternative to oseltamivir
Authors
KeywordsCross-protection
hemagglutinin
highly pathogenic avian influenza virus
human monoclonal antibody
newly emerging H5 viruses
Issue Date2016
PublisherTaylor & Francis Inc. The Journal's web site is located at http://www.tandfonline.com/kmab
Citation
MAbs, 2016, v. 8 n. 6, p. 1156-1166 How to Cite?
AbstractNewly emerging highly pathogenic avian influenza (HPAI) H5N2, H5N3, H5N5, H5N6, H5N8 and H5N9 viruses have been spreading in poultry and wild birds. The H5N6 viruses have also caused 10 human infections with 4 fatal cases in China. Here, we assessed the cross-neutralization and cross-protection of human and mouse monoclonal antibodies against 2 viruses: a HPAI H5N8 virus, A/chicken/Netherlands/14015526/2014 (NE14) and a HPAI H5N6 virus, A/Sichuan/26221/2014 (SC14). The former was isolated from an infected chicken in Netherlands in 2014 and the latter was isolated from an infected human patient in Sichuan, China. We show that antibodies FLA5.10, FLD21.140, 100F4 and 65C6, but not AVFluIgG01, AVFluIgG03, S139/1 and the VRC01 control, potently cross-neutralize the H5N8 NE14 and H5N6 SC14 viruses. Furthermore, we show that a single injection of >1 mg/kg of antibody 100F4 at 4 hours before, or 20 mg/kg antibody 100F4 at 72 hours after, a lethal dose of H5N8 NE14 enables mice to withstand the infection. Finally, we show that a single injection of 0.5 or 1 mg/kg antibody 100F4 prophylactically or 10 mg/kg 100F4 therapeutically outperforms a 5-day course of 10 mg/kg/day oseltamivir treatment against lethal H5N8 NE14 or H5N6 SC14 infection in mice. Our results suggest that further preclinical evaluation of human monoclonal antibodies against newly emerging H5 viruses is warranted. © 2016, © Taylor & Francis Group, LLC.
Persistent Identifierhttp://hdl.handle.net/10722/273970
ISSN
2019 Impact Factor: 4.634
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorRen, H-
dc.contributor.authorWang, G-
dc.contributor.authorWang, S-
dc.contributor.authorChen, Z-
dc.contributor.authorChen, H-
dc.contributor.authorHu, H-
dc.contributor.authorCheng, G-
dc.contributor.authorZhou, P-
dc.date.accessioned2019-08-18T14:52:25Z-
dc.date.available2019-08-18T14:52:25Z-
dc.date.issued2016-
dc.identifier.citationMAbs, 2016, v. 8 n. 6, p. 1156-1166-
dc.identifier.issn1942-0862-
dc.identifier.urihttp://hdl.handle.net/10722/273970-
dc.description.abstractNewly emerging highly pathogenic avian influenza (HPAI) H5N2, H5N3, H5N5, H5N6, H5N8 and H5N9 viruses have been spreading in poultry and wild birds. The H5N6 viruses have also caused 10 human infections with 4 fatal cases in China. Here, we assessed the cross-neutralization and cross-protection of human and mouse monoclonal antibodies against 2 viruses: a HPAI H5N8 virus, A/chicken/Netherlands/14015526/2014 (NE14) and a HPAI H5N6 virus, A/Sichuan/26221/2014 (SC14). The former was isolated from an infected chicken in Netherlands in 2014 and the latter was isolated from an infected human patient in Sichuan, China. We show that antibodies FLA5.10, FLD21.140, 100F4 and 65C6, but not AVFluIgG01, AVFluIgG03, S139/1 and the VRC01 control, potently cross-neutralize the H5N8 NE14 and H5N6 SC14 viruses. Furthermore, we show that a single injection of >1 mg/kg of antibody 100F4 at 4 hours before, or 20 mg/kg antibody 100F4 at 72 hours after, a lethal dose of H5N8 NE14 enables mice to withstand the infection. Finally, we show that a single injection of 0.5 or 1 mg/kg antibody 100F4 prophylactically or 10 mg/kg 100F4 therapeutically outperforms a 5-day course of 10 mg/kg/day oseltamivir treatment against lethal H5N8 NE14 or H5N6 SC14 infection in mice. Our results suggest that further preclinical evaluation of human monoclonal antibodies against newly emerging H5 viruses is warranted. © 2016, © Taylor & Francis Group, LLC.-
dc.languageeng-
dc.publisherTaylor & Francis Inc. The Journal's web site is located at http://www.tandfonline.com/kmab-
dc.relation.ispartofMAbs-
dc.rightsAOM/Preprint Before Accepted: his article has been accepted for publication in [JOURNAL TITLE], published by Taylor & Francis. AOM/Preprint After Accepted: This is an [original manuscript / preprint] of an article published by Taylor & Francis in [JOURNAL TITLE] on [date of publication], available online: http://www.tandfonline.com/[Article DOI]. Accepted Manuscript (AM) i.e. Postprint This is an Accepted Manuscript of an article published by Taylor & Francis in [JOURNAL TITLE] on [date of publication], available online: http://www.tandfonline.com/[Article DOI].-
dc.subjectCross-protection-
dc.subjecthemagglutinin-
dc.subjecthighly pathogenic avian influenza virus-
dc.subjecthuman monoclonal antibody-
dc.subjectnewly emerging H5 viruses-
dc.titleCross-protection of newly emerging HPAI H5 viruses by neutralizing human monoclonal antibodies: A viable alternative to oseltamivir-
dc.typeArticle-
dc.identifier.emailChen, Z: zchenai@hku.hk-
dc.identifier.emailChen, H: hlchen@hku.hk-
dc.identifier.authorityChen, Z=rp00243-
dc.identifier.authorityChen, H=rp00383-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1080/19420862.2016.1183083-
dc.identifier.pmid27167234-
dc.identifier.scopuseid_2-s2.0-84973117979-
dc.identifier.hkuros301351-
dc.identifier.volume8-
dc.identifier.issue6-
dc.identifier.spage1156-
dc.identifier.epage1166-
dc.identifier.isiWOS:000381370000014-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats